Rimegepant + Zavegepant for Migraine

This trial tests two treatments, rimegepant and zavegepant, for relieving acute migraine pain during an Emergency Department visit. Participants will receive either an oral tablet of rimegepant or an intranasal spray of zavegepant and will be monitored for 28 days to assess treatment effectiveness. It is ideal for individuals with migraines severe enough to require emergency care and who have been migraine-free for over 48 hours before their current attack. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive these new treatments.

Earlier studies have shown that rimegepant is safe for treating migraines. Participants taking 75 mg doses reported only minor side effects. It proved safe even for those with other health issues like anxiety or heart problems. Research also shows that rimegepant is well-tolerated for up to a year without serious side effects.

For zavegepant, research indicates it is also safe. The nasal spray effectively treats migraines and usually causes only mild side effects. Long-term studies suggest it is safe to use up to eight times a month for a year. Serious side effects were rare, making it a well-tolerated option for migraine relief.

Unlike the standard treatments for migraines, such as triptans and NSAIDs, Rimegepant and Zavegepant offer a fresh approach by targeting calcitonin gene-related peptide (CGRP) pathways. Rimegepant is taken as an orally disintegrating tablet, which can be especially convenient during a migraine attack, while Zavegepant is delivered through an intranasal spray, providing rapid relief. Researchers are excited about these treatments because they offer new mechanisms of action and delivery methods, potentially providing faster and more effective relief for migraine sufferers who may not respond well to existing medications.

Research has shown that rimegepant, which participants in this trial may receive, effectively treats sudden migraine attacks. In clinical trials, 61.3% of patients experienced pain relief two hours after a single dose, and 81.8% felt relief after four hours. This treatment consistently outperformed placebos in several studies.